Stock Track | 10x Genomics Stock Surges on Long-Term Growth Prospects

Stock Track

Oct 12, 2024

Shares of 10x Genomics, Inc. (TXG) soared by 6.19% on Thursday, October 11, 2024, as investors remained optimistic about the company's long-term growth potential despite weaker-than-expected revenue guidance for the third quarter.

The biotechnology firm, known for its innovative genomics solutions, announced that its Q3 revenue is expected to be around $151.7 million, down 1% from the year-ago period. While this guidance initially weighed on the stock, investors ultimately focused on TXG's overall growth trajectory and reasonable valuation.

According to an analysis by Simply Wall St, TXG's price-to-sales ratio has returned to a level more in line with the broader life sciences industry, reflecting investors' comfort with the company's valuation. The report highlighted that TXG's revenue growth has outpaced the industry average, with a 56% increase over the past three years, including an 11% rise in the previous year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1175597372"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175597372\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175597372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-12 08:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175597372","market":"hk","top_or_hot":-1,"title":"Stock Track | 10x Genomics Stock Surges on Long-Term Growth Prospects","media":"Stock Track","content":"<p>Shares of 10x Genomics, Inc. (TXG) soared by 6.19% on Thursday, October 11, 2024, as investors remained optimistic about the company's long-term growth potential despite weaker-than-expected revenue guidance for the third quarter.</p>\n\n<p>The biotechnology firm, known for its innovative genomics solutions, announced that its Q3 revenue is expected to be around $151.7 million, down 1% from the year-ago period. While this guidance initially weighed on the stock, investors ultimately focused on TXG's overall growth trajectory and reasonable valuation.</p>\n\n<p>According to an analysis by Simply Wall St, TXG's price-to-sales ratio has returned to a level more in line with the broader life sciences industry, reflecting investors' comfort with the company's valuation. The report highlighted that TXG's revenue growth has outpaced the industry average, with a 56% increase over the past three years, including an 11% rise in the previous year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 10x Genomics Stock Surges on Long-Term Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 10x Genomics Stock Surges on Long-Term Growth Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-12 08:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of 10x Genomics, Inc. (TXG) soared by 6.19% on Thursday, October 11, 2024, as investors remained optimistic about the company's long-term growth potential despite weaker-than-expected revenue guidance for the third quarter.</p>\n\n<p>The biotechnology firm, known for its innovative genomics solutions, announced that its Q3 revenue is expected to be around $151.7 million, down 1% from the year-ago period. While this guidance initially weighed on the stock, investors ultimately focused on TXG's overall growth trajectory and reasonable valuation.</p>\n\n<p>According to an analysis by Simply Wall St, TXG's price-to-sales ratio has returned to a level more in line with the broader life sciences industry, reflecting investors' comfort with the company's valuation. The report highlighted that TXG's revenue growth has outpaced the industry average, with a 56% increase over the past three years, including an 11% rise in the previous year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1175597372","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175597372","pubTimestamp":1728694598,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of 10x Genomics, Inc.  soared by 6.19% on Thursday, October 11, 2024, as investors remained optimistic about the company's long-term growth potential despite weaker-than-expected revenue guidance for the third quarter.The biotechnology firm, known for its innovative genomics solutions, announced that its Q3 revenue is expected to be around $151.7 million, down 1% from the year-ago period. While this guidance initially weighed on the stock, investors ultimately focused on TXG's overall gro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"股票轨迹10x Genomics股票因长期增长前景而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"Shares of 10x Genomics, Inc. (TXG) soared by 6.19% on Thursday, October 11, 2024, as investors remained optimistic about the company's long-term growth potential despite weaker-than-expected revenue guidance for the third quarter.\nThe biotechnology firm, known for its innovative genomics solutions, announced that its Q3 revenue is expected to be around $151.7 million, down 1% from the year-ago period. While this guidance initially weighed on the stock, investors ultimately focused on TXG's overall growth trajectory and reasonable valuation.\nAccording to an analysis by Simply Wall St, TXG's price-to-sales ratio has returned to a level more in line with the broader life sciences industry, reflecting investors' comfort with the company's valuation. The report highlighted that TXG's revenue growth has outpaced the industry average, with a 56% increase over the past three years, including an 11% rise in the previous year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}